Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.

Ihle NT, Paine-Murrieta G, Berggren MI, Baker A, Tate WR, Wipf P, Abraham RT, Kirkpatrick DL, Powis G.

Mol Cancer Ther. 2005 Sep;4(9):1349-57.

2.

Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling.

Ihle NT, Williams R, Chow S, Chew W, Berggren MI, Paine-Murrieta G, Minion DJ, Halter RJ, Wipf P, Abraham R, Kirkpatrick L, Powis G.

Mol Cancer Ther. 2004 Jul;3(7):763-72.

3.

Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin.

Wipf P, Minion DJ, Halter RJ, Berggren MI, Ho CB, Chiang GG, Kirkpatrick L, Abraham R, Powis G.

Org Biomol Chem. 2004 Jul 7;2(13):1911-20. Epub 2004 Jun 14.

PMID:
15227545
4.
6.

Inhibition of the signalling enzyme phosphatidylinositol-3-kinase by antitumor ether lipid analogues.

Berggren MI, Gallegos A, Dressler LA, Modest EJ, Powis G.

Cancer Res. 1993 Sep 15;53(18):4297-302.

Supplemental Content

Loading ...
Support Center